Immunological response in the mouse melanoma model after local hyperthermia
/in Hyperthermia, International Publications, Malignant Melanoma /von 2007-05-30 / Physiol Res 2008;57(3):459-65Counterpoint: Hyperthermia with radiation therapy for chest wall recurrences
/in Breast Cancer, Hyperthermia, International Publications /von 2007-03-01 / J Natl Compr Canc Netw 2007 Mar;5(3):345-8Point: Hyperthermia with radiation for chest wall recurrences
/in Breast Cancer, Hyperthermia, International Publications /von 2007-03-01 / J Natl Compr Canc Netw 2007 Mar;5(3):339-44[Malignant peritoneal mesothelioma. Our experienced with triple combined therapy: cytoreduction, intraperitoneal perioperative chemotherapy and hyperthermia]
/in Hyperthermia, International Publications, Malignant Pleural Mesothelioma /von 2007-02-01 / Cir Esp 2007 Feb;81(2):82-6Enhanced T-cell immunity induced by dendritic cells with phagocytosis of heat shock protein 70 gene-transfected tumor cells in early phase of apoptosis
/in Dendritic Cells, Hyperthermia, International Publications /von 2007-01-19 / Cancer Gene Ther. 2007 Apr;14(4):409-20Gene expression in enhanced apoptosis of human lymphoma U937 cells treated with the combination of different free radical generators and hyperthermia
/in Hyperthermia, International Publications, Malignant Lymphoma /von 2007-01-01 / Free Radic. Res. 2007 Jan;41(1):73-81Fever-range thermal stress promotes lymphocyte trafficking across high endothelial venules via an interleukin 6 trans-signaling mechanism
/in Hyperthermia, International Publications /von 2006-12-01 / Nat. Immunol. 2006 Dec;7(12):1299-308Combined use of dendritic cells enhances specific antileukemia immunity by leukemia cell-derived heat shock protein 70 in a mouse model with minimal residual leukemia cells
/in Dendritic Cells, Hyperthermia, International Publications /von 2006-12-01 / Int. J. Hematol. 2006 Dec;84(5):449-58Hyperthermia and immunity. A brief overview
/in Hypernephroma, Hyperthermia, International Publications, Malignant Melanoma /von 2006-11-01 / In Vivo 2006 Nov-Dec;20(6A):689-95
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de